Developed by researchers at the Institute of Chemistry of the University of São Paulo (USP) in São Carlos (SP), the substance "synthetic phosphoethanolamine" is seen by many as a breakthrough able to cure various types of cancer. The problem is that the discovery has not yet passed through all the stages of research, and so lost JUDICIAL AUTHORIZATION for distribution to patients. better understand this issue.
# 7 - The substance
The phosphoethanolamine is a natural substance present in our body. Researchers from São Carlos developed, for about 20 years, the synthetic version (artificial) of this substance, which acts as a kind of "marker" of cancer cells, causing the immune system of patients can destroy these abnormal cells.
# 6 - Justice on the scene
After the discovery of synthetic phosphoethanolamine be announced, patients began to get court orders forcing USP to provide the substance for cancer patients. These decisions are based on the Federal Constitution, which guarantees universal access to health for all Brazilians.
# 5 - And the tests?
The problem is that synthetic fosfoetalonamina may even still be considered a remedy, since it has not gone through all stages of research. It has been tested only in cells and mice lacking the steps that include just human beings.
# 4 - Anvisa and ban
The National Health Surveillance Agency (ANVISA) has to give the approval on research before releasing any new drug, but the agency never examined the phosphoethanolamine. Because of this, in November 2015 they were suspended judicial decisions that determined the distribution to patients.
# 3 - organized Patients
Patients then began to organize to get back to receive the product by pressing government and MPs.
# 2 - Federal Government
The Federal Government, through the Ministry of Science, Technology and Innovation, has announced it will begin testing the phosphoethanolamine from the beginning - making the human trials are still waiting months to get longer.
# 1 - São Paulo Government
But the State Government, via the Cancer Institute of São Paulo, either direct begin testing in humans. Ten patients, not yet determined, would be the first to be tested. If the results are positive, more people will be tested until the drug is approved (or denied if the tests are not positive). However, Anvisa must first authorize the state government to do such tests.